Testing HLX3902 for advanced cancers, especially prostate cancer
Part of Cancer clinical trials.
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer (spread to other parts of the body) that has progressed despite standard treatment
- If you have prostate cancer, you must have tried at least one newer hormone therapy and one or two chemotherapy regimens
- You must have at least one measurable tumor that can be seen on imaging
- Your overall health status is good enough to handle the study (ECOG score 0–1, meaning you can do normal activities or have minor limitations)
- You are willing to provide a tumor tissue sample for testing
- You have not received certain prior treatments within specific timeframes (e.g., no chemotherapy in the last 4 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new daily pill called HLX97 for people with advanced cancers that have stopped responding to standard treatments. It may help if you have a type of breast cancer that is hormone-receptor positive and HER2-negative, or castration-resistant prostate cancer, or non-small cell lung cancer.
Hear when a new mCRPC or Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.